IREN
IREN Limited
There isn't enough reported data to score IREN yet.
USCB
USCB Financial Holdings, Inc.
USCB's fundamentals are mixed: revenue grew 4.2%, but its operating margin fell 4 points to 40%. At 13x earnings, it's trading in line with its usual 13x. Analysts expect earnings to hold roughly steady.
IREN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| N/A | |
| N/A |
IREN's revenue and profitability are currently under pressure. Free cash flow and net leverage aren't meaningful measures for financial services companies like IREN.
USCB Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| N/A | |
| N/A |
USCB's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like USCB.
IREN PE Valuation
IREN has no meaningful PE right now: it lost money over the past year.
USCB PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 9.8x | $20.13 | — |
| Cheap | 11x | $18.10 | -10% |
| Fair | 13x | $20.88 | +3.7% |
| Current | 13x | $20.13 | — |
| Expensive | 17x | $26.97 | +34% |
Historical ranges are pointers, not guarantees.
USCB's PE is in its fair range at 13x. On analysts' estimates for next year's earnings, today's price would be 9.8x, in its cheap range.
IREN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect IREN's losses to grow, with revenue growing. However, they disagree widely on these estimates.
USCB Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Moderate |
Analysts expect USCB's revenue to grow, but its profitability to weaken.
IREN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.96 | -347% |
| Q2 2026 | -$2.22 | -988% |
| Q1 2026 | $0.51 | +$1.10 |
| Q4 2025 | $1.18 | +$1.62 |
| Q3 2025 | $1.60 | +$1.99 |
| Q2 2025 | $0.25 | +$0.45 |
| Q1 2025 | -$0.59 | -$0.43 |
| Q4 2024 | -$0.44 | -$0.15 |
IREN has swung to a loss: it lost $3.96 per share over the past year, after a profit the year before.
USCB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.05 | +27% |
| Q3 2026 | $1.61 | +1.9% |
| Q2 2026 | $1.55 | +4.7% |
| Q1 2026 | $1.46 | +5% |
| Q4 2025 | $1.33 | +7.3% |
| Q3 2025 | $1.58 | +52% |
| Q2 2025 | $1.48 | +68% |
| Q1 2025 | $1.39 | +78% |
| Q4 2024 | $1.24 | +48% |
USCB has the edge over IREN on earnings quality, reporting a profit while its opponent remains loss making.
IREN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $228M | -5.1% |
| Q2 2026 | $137.2M | -27% |
| Q1 2026 | $144.8M | 0% |
| Q4 2025 | $184.7M | +59% |
| Q3 2025 | $240.3M | +355% |
| Q2 2025 | $187.3M | +230% |
| Q1 2025 | $144.8M | +168% |
| Q4 2024 | $116.1M | +176% |
IREN's revenue has held roughly level: $228M last quarter, down 5.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -82% | -50 points |
| Q2 2026 | -452% | -461 points |
| Q1 2026 | -161% | -180 points |
| Q4 2025 | -63% | -79 points |
| Q3 2025 | -32% | +57 points |
| Q2 2025 | 9% | +49 points |
| Q1 2025 | 19% | +8 points |
| Q4 2024 | 15% | +21 points |
IREN's operating margin was −82% last quarter, down 50 points from the same quarter a year ago.
USCB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $27M | +8.1% |
| Q2 2026 | $27.9M | +15% |
| Q1 2026 | $26.2M | +15% |
| Q4 2025 | $18M | -22% |
| Q3 2025 | $25M | +16% |
| Q2 2025 | $24.4M | +19% |
| Q1 2025 | $22.8M | +30% |
| Q4 2024 | $23M | +46% |
USCB's revenue is growing: $27M last quarter, up 8.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 45% | -2.1 points |
| Q2 2026 | 45% | +1.5 points |
| Q1 2026 | 45% | +0.4 points |
| Q4 2025 | 18% | -21 points |
| Q3 2025 | 47% | +4.8 points |
| Q2 2025 | 44% | +4.2 points |
| Q1 2025 | 44% | +10 points |
| Q4 2024 | 40% | +17 points |
USCB has the edge over IREN on profitability, with a higher operating margin.
IREN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.6B | -$1.6B |
| Q2 2026 | $482.2M | +2895% |
| Q1 2026 | -$873.8M | -$523.1M |
| Q4 2025 | -$468M | -$334M |
| Q3 2025 | -$38M | +$349.4M |
| Q2 2025 | $16.1M | +$179M |
| Q1 2025 | -$350.7M | -$128.7M |
| Q4 2024 | -$134M | -$105.2M |
IREN's free cash flow was −$2.5B over the past year, against −$507M the year before. Free cash flow isn't a meaningful measure for financial services companies like IREN.
USCB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $13.9M | -30% |
| Q2 2026 | $24.2M | +35% |
| Q1 2026 | $15M | +2.6% |
| Q4 2025 | -$10.1M | -$7M |
| Q3 2025 | $20M | +80% |
| Q2 2025 | $18M | +1% |
| Q1 2025 | $14.6M | +84% |
| Q4 2024 | -$3.1M | +$2.9M |
USCB has the edge over IREN on cash generation, producing positive trailing cash flow while its opponent burns cash.
IREN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +26% | +82.4M shares |
| 1 year | +10% | +36.9M shares |
| 3 years | +511% | +333M shares |
| 5 years | +624% | +344M shares |
| Available history | +2346% | +382M shares |
IREN has 399M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
USCB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -88.3K shares |
| 1 year | +1.5% | +276K shares |
| 3 years | -5.9% | -1.2M shares |
USCB has the edge over IREN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $1M |
| Q4 2025 | — |
| Q3 2025 | $34.4M |
| Q2 2025 | — |
| Q1 2025 | $174,000 |
| Q4 2024 | — |
USCB spent $1M buying back its own shares over the past year, down 97% from the year before.
IREN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 157.6x | High |
| Q4 2025 | 22.2x | High |
| Q3 2025 | 4.1x | High |
| Q2 2025 | 2.0x | Moderate |
| Q1 2025 | 3.3x | Elevated |
| Q4 2024 | -4.6x | Net Cash |
| Q3 2024 | -16.7x | Net Cash |
| Q2 2024 | -15.9x | Net Cash |
IREN's net debt is more than 20 years of its operating earnings (EBITDA), up from 3.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like IREN.
USCB Net Leverage
IREN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.3 | Neutral |
| Stochastic | 8.2 | Oversold |
IREN's weekly RSI is 33 (neutral) and its Stochastic is 8 (oversold).
USCB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.9 | Neutral |
| Stochastic | 14.9 | Oversold |
USCB's weekly RSI is 44 (neutral) and its Stochastic is 15 (oversold).
IREN PE vs Financial Services Sector
| Metric | IREN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
IREN has no meaningful PE right now: it lost money over the past year.
USCB PE vs Financial Services Sector
| Metric | USCB | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 13x | 4% below |
| PE % | 43 | 66 | 23 pts below |
USCB is trading at 13x earnings, in line with the Financial Services sector's median of 13x.
IREN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.8 | 35% below |
| 20 week MA | $36.2 | 46% below |
| 50 week MA | $42.8 | 54% below |
| 100 week MA | $32.0 | 39% below |
| 200 week MA | $19.1 | 2.1% above |
IREN has fallen below most of its moving averages, though it's still 2.1% above its 200-week average.
USCB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.2 | 4.9% below |
| 20 week MA | $21.7 | 7.1% below |
| 50 week MA | $20.1 | 0.3% above |
| 100 week MA | $18.7 | 7.4% above |
| 200 week MA | $15.6 | 29% above |
USCB has the edge over IREN on trend strength, trading above more of its moving averages.
IREN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.8 | $17.2 | -31% |
| 2022 | $17.2 | $1.19 | -93% |
| 2023 | $1.19 | $7.15 | +501% |
| 2024 | $7.15 | $10.7 | +50% |
| 2025 | $10.7 | $40.3 | +276% |
| 2026 YTD | $40.3 | $19.5 | -52% |
IREN's yearly returns have swung widely, from +501% in 2023 to −93% in 2022. It's down 52% so far in 2026.
USCB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $10.8 | $14.6 | +35% |
| 2022 | $14.6 | $12.5 | -15% |
| 2023 | $12.5 | $12.3 | -1.7% |
| 2024 | $12.3 | $17.7 | +45% |
| 2025 | $17.7 | $18.7 | +5.8% |
| 2026 YTD | $18.7 | $20.1 | +7.5% |
USCB has the edge over IREN on returns for 2026, with the stronger performance.